SALARIUS PHARMACEUTICALS, INC.
2450 Holcombe Blvd., Suite X
Houston, Texas 77021
June 2, 2023
VIA EDGAR
Office of Life Sciences
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
| Re: | Salarius Pharmaceuticals, Inc. | ||||
| Registration Statement on Form S-3 | |||||
| Filed May 26, 2023 | |||||
| File No. 333-272249 | |||||
| Request for Acceleration of Effective Date | |||||
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Salarius Pharmaceuticals, Inc. hereby requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form S-3 and declare such Registration Statement effective as of 5:00 p.m., Eastern Time, on June 6, 2023, or as soon thereafter as possible.
Please direct any questions or comments concerning this request to Stephen M. Nicolai of Hogan Lovells US LLP at (267) 675-4642. Also, please notify Mr. Nicolai when this request for acceleration has been granted.
Very truly yours,
SALARIUS PHARMACEUTICALS, INC.
By: /s/ Mark J. Rosenblum
Name: Mark J. Rosenblum
Title: Chief Financial Officer